Bookmark
Forward
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
Sarah N Lauder, Bart Vanhaesebroeck, Awen Gallimore
British journal of cancer 2021 Aug
Sizes of these terms reflect their relevance to your search.
Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice. © 2021. The Author(s).
Citation
Sarah N Lauder, Bart Vanhaesebroeck, Awen Gallimore.
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
British journal of cancer.
2021 Aug;125(4):467-469
Mesh Tags
Animals
Antigens, CD
Class I Phosphatidylinositol 3-Kinases
Drug Resistance, Neoplasm
Drug Synergism
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Mice
Neoplasms
Tumor Microenvironment
Xenograft Model Antitumor Assays
Lymphocyte Activation Gene 3 Protein
Substances
Antigens, CD
Immune Checkpoint Inhibitors
Class I Phosphatidylinositol 3-Kinases
PIK3CD protein, human
Lymphocyte Activation Gene 3 Protein
PMID: 33824480
View Full Text